Arm A (relapsed/refractory CNS tumors) for Ependymoma

St. Jude Children's Research Hospital, Memphis, TN
Ependymoma+7 More ConditionsB7-H3-CAR T cells - Drug
Eligibility
< 65
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing if a new way of delivering cancer-fighting cells to people with brain tumors is safe. Participants will get 6 doses given over 8 weeks.

Eligible Conditions
  • Diffuse Midline Glioma, H3 K27M-Mutant
  • Ependymoma
  • Brain Tumor
  • Glioblastoma
  • Medulloblastoma
  • Brain Tumors
  • Atypical Teratoid/Rhabdoid Tumor

Treatment Effectiveness

Study Objectives

1 Primary · 1 Secondary · Reporting Duration: Eight (8) weeks after the first B7-H3-CAR T-cell infusion or 7 days after the sixth B7-H3-CAR T cell infusion, whichever is longer

Day 7
Maximum tolerated dose (MTD)
Eight (8) weeks post B7-H3-CAR T-cell infusion
Sustained objective radiographic response

Trial Safety

Awards & Highlights

No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

2 Treatment Groups

Arm A (relapsed/refractory CNS tumors)
1 of 2
Arm B (brainstem high-grade neoplasms)
1 of 2

Experimental Treatment

36 Total Participants · 2 Treatment Groups

Primary Treatment: Arm A (relapsed/refractory CNS tumors) · No Placebo Group · Phase 1

Arm A (relapsed/refractory CNS tumors)
Drug
Experimental Group · 1 Intervention: B7-H3-CAR T cells · Intervention Types: Drug
Arm B (brainstem high-grade neoplasms)
Drug
Experimental Group · 1 Intervention: B7-H3-CAR T cells · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: eight (8) weeks after the first b7-h3-car t-cell infusion or 7 days after the sixth b7-h3-car t cell infusion, whichever is longer

Who is running the clinical trial?

St. Jude Children's Research HospitalLead Sponsor
409 Previous Clinical Trials
5,302,594 Total Patients Enrolled
8 Trials studying Ependymoma
1,689 Patients Enrolled for Ependymoma
Kelsey Bertrand, MD, MScPrincipal InvestigatorSt. Jude Children's Research Hospital
Giedre Krenciute, PhDPrincipal InvestigatorSt. Jude Children's Research Hospital
Christopher DeRenzo, MDPrincipal InvestigatorSt. Jude Children's Research Hospital

Eligibility Criteria

Age < 65 · All Participants · 7 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

How precarious is Arm A (relapsed/refractory CNS tumors) for the participants?

"Though limited efficacy and safety data is available, our team at Power assessed Arm A's (relapsed/refractory CNS tumors) security to be a 1 on the 3-point scale." - Anonymous Online Contributor

Unverified Answer

Are any openings available for patients to join this experiment?

"Unfortunately, this particular clinical trial is not actively looking for participants as of now. The most recent edit on the study's page was made on April 18th 2023. However, 860 other trials are currently recruiting patients for their studies." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.